000963 华东医药
午间休市 12-31 11:30:00
资讯
新帖
简况
佐力药业，被700亿华东医药“追堵”
蓝鲸财经 · 00:24
佐力药业，被700亿华东医药“追堵”
华东医药：创新转型进入密集收获期
证券之星 · 12-30 11:34
华东医药：创新转型进入密集收获期
股市必读：华东医药（000963）12月26日董秘有最新回复
证券之星 · 12-29 01:38
股市必读：华东医药（000963）12月26日董秘有最新回复
华东医药：4mg组疗效略优于2mg组
证券之星 · 12-24
华东医药：4mg组疗效略优于2mg组
华东医药：HDM1002减重效果呈剂量依赖性
证券之星 · 12-15
华东医药：HDM1002减重效果呈剂量依赖性
华东医药：利那拉生酯进入2025年国家医保目录
证券之星 · 12-15
华东医药：利那拉生酯进入2025年国家医保目录
华东医药：爱拉赫未进医保因成本与支付标准存差距
证券之星 · 12-15
华东医药：爱拉赫未进医保因成本与支付标准存差距
华东医药（000963）披露回购注销部分限制性股票减少注册资本暨通知债权人公告，12月9日股价下跌1.83%
证券之星 · 12-09
华东医药（000963）披露回购注销部分限制性股票减少注册资本暨通知债权人公告，12月9日股价下跌1.83%
华东医药最新公告：全资子公司产品及合作产品纳入国家医保及商保创新药目录
证券之星 · 12-07
华东医药最新公告：全资子公司产品及合作产品纳入国家医保及商保创新药目录
华东医药（000963）披露限制性股票激励计划第三个解除限售期股份上市流通提示，12月5日股价下跌0.59%
证券之星 · 12-05
华东医药（000963）披露限制性股票激励计划第三个解除限售期股份上市流通提示，12月5日股价下跌0.59%
华东医药：DR10624降低甘油三酯最高达74.5%
证券之星 · 11-21
华东医药：DR10624降低甘油三酯最高达74.5%
华东医药：江西云分途科技有限公司与我司无任何关系
证券之星 · 11-21
华东医药：江西云分途科技有限公司与我司无任何关系
华东医药：爱拉赫2025年1-9月销售收入超4500万元
证券之星 · 11-20
华东医药：爱拉赫2025年1-9月销售收入超4500万元
华东医药：HDM1002预计明年下半年获三期顶线数据
证券之星 · 11-20
华东医药：HDM1002预计明年下半年获三期顶线数据
华东医药：炎朵供货时间尚未最终确定
证券之星 · 11-20
华东医药：炎朵供货时间尚未最终确定
华东医药（000963）披露全资子公司获得药品补充申请批准通知书，11月17日股价下跌2.22%
证券之星 · 11-17
华东医药（000963）披露全资子公司获得药品补充申请批准通知书，11月17日股价下跌2.22%
华东医药最新公告：全资子公司获得索米妥昔单抗注射液常规批准
证券之星 · 11-17
华东医药最新公告：全资子公司获得索米妥昔单抗注射液常规批准
华东医药(000963.SZ)：罗氟司特乳膏(ZORYVE®)0.15%上市许可申请获得受理
智通财经 · 11-11
华东医药(000963.SZ)：罗氟司特乳膏(ZORYVE®)0.15%上市许可申请获得受理
华东医药（000963）披露控股股东部分股份质押及解除质押，11月11日股价上涨0.31%
证券之星 · 11-11
华东医药（000963）披露控股股东部分股份质押及解除质押，11月11日股价上涨0.31%
华东医药最新公告：全资子公司收到罗氟司特乳膏上市许可申请受理通知书
证券之星 · 10-31
华东医药最新公告：全资子公司收到罗氟司特乳膏上市许可申请受理通知书
加载更多
公司概况
公司名称：
华东医药股份有限公司
所属行业：
零售业
上市日期：
2000-01-27
主营业务：
华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。公司凭借优秀的ESG治理能力，WINDESG评级从A级提升至AA级，此外，公司目前MSCIESG评级A级，深交所国证ESG评级AA级，并且获得2024《新财富》杂志“ESG最佳实践”,E药经理人“2025生物医药可持续价值领航奖”等荣誉。
发行价格：
5.76
{"stockData":{"symbol":"000963","market":"SZ","secType":"STK","nameCN":"华东医药","latestPrice":39.34,"timestamp":1767156921000,"preClose":39.06,"halted":0,"volume":4256311,"delay":0,"changeRate":0.0072,"floatShares":1753000000,"shares":1754000000,"eps":2.1082,"marketStatus":"午间休市","change":0.28,"latestTime":"12-31 11:30:00","open":38.81,"high":39.45,"low":38.72,"amount":167000000,"amplitude":0.0187,"askPrice":39.34,"askSize":95,"bidPrice":39.32,"bidSize":158,"shortable":0,"etf":0,"ttmEps":2.1082,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767157200000},"marketStatusCode":3,"adr":0,"adjPreClose":39.06,"symbolType":"stock","openAndCloseTimeList":[[1767144600000,1767151800000],[1767157200000,1767164400000]],"highLimit":42.97,"lowLimit":35.15,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1754021048,"isCdr":false,"pbRate":2.84,"roa":"--","peRate":18.660469,"roe":"11.39%","epsLYR":2.0046,"committee":0.377386,"marketValue":69003000000,"turnoverRate":0.0024,"status":0,"floatMarketCap":68978000000},"requestUrl":"/m/hq/s/000963","defaultTab":"news","newsList":[{"id":"2595716668","title":"佐力药业，被700亿华东医药“追堵”","url":"https://stock-news.laohu8.com/highlight/detail?id=2595716668","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595716668?lang=zh_cn&edition=full","pubTime":"2025-12-31 00:24","pubTimestamp":1767111866,"startTime":"0","endTime":"0","summary":"文｜《投资者网》蔡俊最近，佐力药业不平静。外部，华东医药与公司的诉讼暂告段落，但还未迎来终局。其实，华东医药起诉的核心是与公司争夺百令系列产品。截至目前，公司、华东医药的市值分别约120亿元、700亿元。留“后手”+再造新曲线几乎在收购未来生物的同期，佐力药业与华东医药发布纠纷进展。根据公告，法院驳回华东医药子公司的全部诉讼请求，并要求其负担案件受理费。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1766906460012125486","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0077","BK0188","BK0196","BK0209","300181","BK0175","BK0132","BK0187","000963","BK0042","LU1969619763.USD","LU2328871848.SGD","BK0239","BK0183"],"gpt_icon":0},{"id":"2595763376","title":"华东医药：创新转型进入密集收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2595763376","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595763376?lang=zh_cn&edition=full","pubTime":"2025-12-30 11:34","pubTimestamp":1767065645,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药12月29日在投资者关系平台上答复投资者关心的问题。真是为公司捏把汗呀 老师是了解全面状况的 盼陈老师给这些老股东们一个实底就好了 谢谢华东医药回复：您好！创新转型一直是公司的核心战略方向。对于创新药业务收入，公司具备充分的战略信心与执行保障，目前公司已将资源配置、考核机制全面向创新业务倾斜，管理层及全体员工均已明确目标、凝聚共识。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000016092.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","LU1969619763.USD","BK0175","BK0187","BK0196","BK0209","BK0188","000963","BK0132","LU2328871848.SGD"],"gpt_icon":0},{"id":"2595727323","title":"股市必读：华东医药（000963）12月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2595727323","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595727323?lang=zh_cn&edition=full","pubTime":"2025-12-29 01:38","pubTimestamp":1766943491,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，华东医药报收于39.7元，下跌0.82%，换手率0.27%，成交量4.74万手，成交额1.89亿元。董秘最新回复投资者： 您好，请问截止到2025年12月24日公司股东数是多少？此外，公司也可在严格核实股东身份信息后按相关规定告知。联系电话：0571-89903300，公司邮箱：ir@eastchinapharm.com。当日关注点来自交易信息汇总：12月26日主力资金净流出2005.09万元，显示主力短期内可能持谨慎态度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900000575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963","BK0175","BK0196","BK0209","BK0132","BK0187","BK0188","LU1969619763.USD","LU2328871848.SGD","BK0183"],"gpt_icon":0},{"id":"2593423049","title":"华东医药：4mg组疗效略优于2mg组","url":"https://stock-news.laohu8.com/highlight/detail?id=2593423049","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593423049?lang=zh_cn&edition=full","pubTime":"2025-12-24 11:37","pubTimestamp":1766547457,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药12月23日在投资者关系平台上答复投资者关心的问题。HDM1005目前的二期数据展示的是实测值，在经过治疗组、基线体重等影响因素校正后 4mg 组疗效略优于 2mg 组；同时，二期治疗时间短，且需要从低剂量逐渐滴定至目标剂量，稳定治疗时长较短是 2mg 和 4mg 疗效接近的主要原因。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400014706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963","BK0196","LU2328871848.SGD","LU1969619763.USD","BK0209","BK0188","BK0183","BK0187","BK0132","BK0175"],"gpt_icon":0},{"id":"2591616710","title":"华东医药：HDM1002减重效果呈剂量依赖性","url":"https://stock-news.laohu8.com/highlight/detail?id=2591616710","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591616710?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:15","pubTimestamp":1765786516,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药12月15日在投资者关系平台上答复投资者关心的问题。HDM1002减重Ⅱ期临床研究结果显示，HDM1002 100 mg BID组、HDM1002 200 mg BID组、HDM1002 400 mg QD组及安慰剂组给药12周后体重较基线变化百分比分别为-4.63%、-6.08%、-6.83%和-2.88%。从Ⅱ期数据来看，HDM1002体重降低的效果呈现剂量依赖性，随着剂量的增加，减重效应也随之提升；HDM1002 12周减重未达到平台期，体重下降的趋势仍然明显，且随着用药时间的延长，各剂量组的减重效果均有进一步提升的潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500015748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0183","BK0209","BK0187","BK0132","000963","LU2328871848.SGD","LU1969619763.USD","BK0175","BK0196"],"gpt_icon":0},{"id":"2591616160","title":"华东医药：利那拉生酯进入2025年国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2591616160","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591616160?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:00","pubTimestamp":1765785626,"startTime":"0","endTime":"0","summary":"利那拉生酯是生诺医药与Cinclus Pharma合作开发的新一代钾离子竞争性酸阻滞剂类药物，用于治疗消化系统疾病，目前，该药物针对反流性食管炎适应症已在国内获批并成功进入2025年国家医保目录。根据协议条款，生诺医药作为MAH持有人，负责利那拉生酯的研发、注册、生产和供应，在协议签署并生效后，生诺医药将获得首付款，以及相应里程碑付款；公司将负责利那拉生酯在中国大陆的商业化推广工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500014168.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","LU1969619763.USD","BK0188","BK0196","BK0209","BK0187","LU2328871848.SGD","000963","BK0175","BK0132"],"gpt_icon":0},{"id":"2591261616","title":"华东医药：爱拉赫未进医保因成本与支付标准存差距","url":"https://stock-news.laohu8.com/highlight/detail?id=2591261616","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591261616?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:00","pubTimestamp":1765785623,"startTime":"0","endTime":"0","summary":"今年公司两大王牌新药，利纳西普因为备货问题还未上市，爱拉赫未进医保，公司内部是否有些问题，领导怎么看？爱拉赫作为公司引进的进口创新药产品，没有被纳入2025年国家医保目录的主要原因是，目前其综合成本及海外市场价格与国内医保支付标准之间尚存在差距。此外，爱拉赫中国市场包装版本已于11月初正式商业化并开出全国首张处方。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500014165.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963","BK0175","BK0196","BK0209","BK0132","BK0187","BK0188","LU1969619763.USD","LU2328871848.SGD","BK0183"],"gpt_icon":0},{"id":"2590342506","title":"华东医药（000963）披露回购注销部分限制性股票减少注册资本暨通知债权人公告，12月9日股价下跌1.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590342506","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590342506?lang=zh_cn&edition=full","pubTime":"2025-12-09 22:24","pubTimestamp":1765290265,"startTime":"0","endTime":"0","summary":"截至2025年12月9日收盘，华东医药报收于41.74元，较前一交易日下跌1.83%，最新总市值为732.13亿元。该股当日开盘42.58元，最高43.05元，最低41.6元，成交额达2.93亿元，换手率为0.4%。公司近日发布公告称，因部分激励对象离职或绩效考核未达标，拟回购注销28.42万股限制性股票，回购价格为22.85元/股，资金来源为自有资金。本次回购注销后，公司总股本将由1,754,021,048股减少至1,753,736,848股，注册资本相应减少。公司债权人可在公告披露之日起45日内申报债权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900040990.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","000963","BK0188","BK0183","LU1969619763.USD","BK0132","BK0187","BK0196","BK0175","LU2328871848.SGD"],"gpt_icon":0},{"id":"2589879688","title":"华东医药最新公告：全资子公司产品及合作产品纳入国家医保及商保创新药目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589879688","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589879688?lang=zh_cn&edition=full","pubTime":"2025-12-07 16:20","pubTimestamp":1765095633,"startTime":"0","endTime":"0","summary":"华东医药(000963.SZ)公告称，公司全资子公司中美华东的乌司奴单抗注射液调整至常规目录管理，支付范围变动。合作产品塞纳帕利胶囊、戊二酸利那拉生酯胶囊被纳入新版药品目录，泽沃基奥仑赛注射液被纳入商保创新药目录。新版药品目录自2026年1月1日起执行，预计将有助于公司产品市场推广。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120700003965.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","159992","BK0183","LU2328871848.SGD","BK0196","BK0209","BK1161","LU1969619763.USD","BK0132","BK1574","000963","BK0187","06978","BK0175"],"gpt_icon":0},{"id":"2589813522","title":"华东医药（000963）披露限制性股票激励计划第三个解除限售期股份上市流通提示，12月5日股价下跌0.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589813522","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589813522?lang=zh_cn&edition=full","pubTime":"2025-12-05 22:25","pubTimestamp":1764944702,"startTime":"0","endTime":"0","summary":"截至2025年12月5日收盘，华东医药报收于42.13元，较前一交易日下跌0.59%，最新总市值为738.97亿元。近日，华东医药发布关于2022年限制性股票激励计划首次授予限制性股票第三个解除限售期解除限售股份上市流通的提示性公告。本次符合解除限售条件的激励对象共77人，可解除限售的限制性股票数量为127.512万股，占公司总股本的0.07%。本次解除限售股份上市流通日为2025年12月10日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500040660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0188","BK0209","BK0187","BK0183","000963","BK0196","LU2328871848.SGD","BK0132","LU1969619763.USD"],"gpt_icon":0},{"id":"2585190864","title":"华东医药：DR10624降低甘油三酯最高达74.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585190864","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585190864?lang=zh_cn&edition=full","pubTime":"2025-11-21 15:48","pubTimestamp":1763711289,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药11月21日在投资者关系平台上答复投资者关心的问题。投资者提问：DR10624作为全球首个GLP-1R/GCGR/FGF21R三重激动剂，II期数据显示肝脏脂肪降幅超89%，具First-in-class潜力。公司DR10624的重度高甘油三酯血症2期临床结果已在AHA2025大会以开场报告的形式发布，连续给药12周，其降低甘油三酯最高达74.5%，减少肝脏脂肪最高达67%。未来如达成明确合作协议，公司将严格按照信息披露规则履行披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100018775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963","LU2328871848.SGD","LU1969619763.USD","BK0187","BK0132","BK0188","BK0209","BK0183","BK0175","BK0196"],"gpt_icon":0},{"id":"2585971421","title":"华东医药：江西云分途科技有限公司与我司无任何关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2585971421","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585971421?lang=zh_cn&edition=full","pubTime":"2025-11-21 15:24","pubTimestamp":1763709875,"startTime":"0","endTime":"0","summary":"近日公司已关注到，有不法分子伪造华东医药印章，冒用华东医药身份信息，将华东医药冒名登记为江西云分途科技有限公司股东，公司已于2025年11月19日在公司官网发布严正声明。对此，公司再次严正声明：江西云分途科技有限公司与华东医药及所属公司无任何隶属与股权关系，也不存在任何投资、合作、业务等关系，其一切行为均与华东医药无关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100017811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963","LU2328871848.SGD","LU1969619763.USD","BK0187","BK0132","BK0188","BK0209","BK0183","BK0175","BK0196"],"gpt_icon":0},{"id":"2584189842","title":"华东医药：爱拉赫2025年1-9月销售收入超4500万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2584189842","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584189842?lang=zh_cn&edition=full","pubTime":"2025-11-20 16:15","pubTimestamp":1763626519,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药11月20日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，根据AbbVie披露，2025年前三季度，ELAHERE的全球净收入为5.08亿美元，其中美国市场的净收入为4.53亿美元。贵公司是否预估过爱拉赫在大中华区的营收规模？目前销售情况如何？谢谢华东医药回复：您好！爱拉赫中国市场包装版本已于本月初正式商业化并开出全国首张处方。此前，爱拉赫依托“港澳药械通”政策率先打开市场，2025年1-9月已实现销售收入超4500万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000020350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0209","BK0175","BK0132","BK0187","000963","BK0183","BK0188","LU2328871848.SGD","LU1969619763.USD"],"gpt_icon":0},{"id":"2584186076","title":"华东医药：HDM1002预计明年下半年获三期顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2584186076","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584186076?lang=zh_cn&edition=full","pubTime":"2025-11-20 16:15","pubTimestamp":1763626518,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)11月20日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，请问HDM1002减肥三期的中期数据怎么样，预计什么时候能公布其三期的部分数据华东医药回复：您好！HDM1002预计于明年下半年获得体重管理适应症的三期顶线数据。公司后续将根据项目进展以公告/新闻的形式或者选择在国际重要学术会议上发布，请您关注后续的相关信息。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000020347.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0175","BK0188","BK0209","BK0187","BK0183","LU1969619763.USD","000963","BK0132","LU2328871848.SGD"],"gpt_icon":0},{"id":"2584118624","title":"华东医药：炎朵供货时间尚未最终确定","url":"https://stock-news.laohu8.com/highlight/detail?id=2584118624","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584118624?lang=zh_cn&edition=full","pubTime":"2025-11-20 16:12","pubTimestamp":1763626331,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)11月20日在投资者关系平台上答复投资者关心的问题。投资者提问：关于“炎朵”的沟通有进展没？对方什么时间开始供货？有相关计划吗？华东医药回复：您好！炎朵因合作方供货时间尚未最终确定，具体时间计划存在不确定性。公司正积极与合作方保持密切沟通，推动相关事宜。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000020031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0183","BK0209","BK0187","BK0132","000963","LU2328871848.SGD","LU1969619763.USD","BK0175","BK0196"],"gpt_icon":0},{"id":"2584215606","title":"华东医药（000963）披露全资子公司获得药品补充申请批准通知书，11月17日股价下跌2.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584215606","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584215606?lang=zh_cn&edition=full","pubTime":"2025-11-17 22:13","pubTimestamp":1763388792,"startTime":"0","endTime":"0","summary":"截至2025年11月17日收盘，华东医药报收于42.19元，较前一交易日下跌2.22%，最新总市值为740.02亿元。近日，华东医药发布公告称，其全资子公司杭州中美华东制药有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，索米妥昔单抗注射液由附条件批准转为常规批准，适应症为既往接受过1-3线系统性治疗的叶酸受体α阳性铂类耐药的上皮性卵巢癌、输卵管癌或原发性腹膜癌成年患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700036607.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0209","BK0132","LU2328871848.SGD","000963","LU1969619763.USD","BK0175","BK0196","BK0183","BK0187"],"gpt_icon":0},{"id":"2584649601","title":"华东医药最新公告：全资子公司获得索米妥昔单抗注射液常规批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2584649601","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584649601?lang=zh_cn&edition=full","pubTime":"2025-11-17 17:40","pubTimestamp":1763372440,"startTime":"0","endTime":"0","summary":"华东医药(000963.SZ)公告称，公司全资子公司中美华东收到NMPA核准签发的《药品补充申请批准通知书》，索米妥昔单抗注射液（爱拉赫/ELAHERE）由附条件批准转为常规批准的补充申请获得批准。该药物适用于既往接受过1-3线系统性治疗的叶酸受体α（FRα）阳性的铂类耐药的上皮性卵巢癌、输卵管癌或原发性腹膜癌成年患者。本次补充申请获批是基于验证性Ⅲ期临床试验MIRASOL的结果，该试验显示索米妥昔单抗在FRα阳性PROC患者中提供了具有临床意义的获益。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700024055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0183","LU2328871848.SGD","BK0196","BK0209","LU1969619763.USD","BK0132","000963","BK0187","BK0175"],"gpt_icon":0},{"id":"2582612352","title":"华东医药(000963.SZ)：罗氟司特乳膏(ZORYVE®)0.15%上市许可申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2582612352","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582612352?lang=zh_cn&edition=full","pubTime":"2025-11-11 17:39","pubTimestamp":1762853979,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华东医药 发布公告，2025年11月10日，公司全资子公司杭州中美华东制药有限公司收到国家药品监督管理局签发的《受理通知书》，罗氟司特乳膏0.15%上市许可申请获得受理。中国Ⅲ期临床研究结果显示，罗氟司特乳膏0.15%在6岁及以上轻度至中度特应性皮炎受试者中表现出积极的疗效和良好的安全性，达成研究主要终点，整体有效性、安全性数据与合作方Arcutis公司海外研究数据类似，支持其国内申报上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华东医药(000963.SZ)：罗氟司特乳膏(ZORYVE®)0.15%上市许可申请获得受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0188","BK0209","LU2328871848.SGD","BK0187","000963","BK0132","BK0175","BK0196","LU1969619763.USD"],"gpt_icon":0},{"id":"2582354954","title":"华东医药（000963）披露控股股东部分股份质押及解除质押，11月11日股价上涨0.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582354954","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582354954?lang=zh_cn&edition=full","pubTime":"2025-11-11 17:22","pubTimestamp":1762852957,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，华东医药报收于42.6元，较前一交易日上涨0.31%，最新总市值为747.21亿元。公司近日发布公告称，接到控股股东中国远大集团有限责任公司通知，远大集团将其持有的公司部分股份办理了质押和解除质押。本次合计质押39,160,000股，占公司总股本2.23%，质押用途为续贷质押；合计解除质押40,370,000股，占公司总股本2.30%。本次变动后，远大集团累计质押股份占其所持股份比例为19.52%，占公司总股本8.13%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100027851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU2328871848.SGD","BK0132","BK0209","BK0183","000963","BK0175","LU1969619763.USD","BK0187","BK0188"],"gpt_icon":0},{"id":"2579450545","title":"华东医药最新公告：全资子公司收到罗氟司特乳膏上市许可申请受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2579450545","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579450545?lang=zh_cn&edition=full","pubTime":"2025-10-31 18:30","pubTimestamp":1761906623,"startTime":"0","endTime":"0","summary":"华东医药公告称，公司全资子公司中美华东收到国家药品监督管理局签发的《受理通知书》，罗氟司特乳膏0.3%上市许可申请获得受理。罗氟司特乳膏是中美华东与美国Arcutis公司于2023年8月签署合作协议引进的创新皮肤外用制剂产品，中美华东拥有该产品在大中华区及东南亚的独家许可。此次上市许可申请获得受理是该系列产品研发进程中的重要里程碑，将进一步提升公司在自免皮肤治疗领域的竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100039981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","BK0188","LU1969619763.USD","LU2328871848.SGD","BK0183","BK0132","BK0196","BK0187","BK0175","000963"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767156968952,"stockEarnings":[{"period":"1week","weight":-0.0308},{"period":"1month","weight":-0.07},{"period":"3month","weight":-0.0599},{"period":"6month","weight":-0.0242},{"period":"1year","weight":0.1215},{"period":"ytd","weight":0.1533}],"compareEarnings":[{"period":"1week","weight":0.0115},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0212},{"period":"6month","weight":0.1456},{"period":"1year","weight":0.1637},{"period":"ytd","weight":0.183}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华东医药股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"68793人(较上一季度减少1.50%)","perCapita":"25487股","listingDate":"2000-01-27","address":"浙江省杭州市拱墅区中山北路439号4、7楼","registeredCapital":"175402万元","survey":" 华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。公司凭借优秀的ESG治理能力，WINDESG评级从A级提升至AA级，此外，公司目前MSCIESG评级A级，深交所国证ESG评级AA级，并且获得2024《新财富》杂志“ESG最佳实践”,E药经理人“2025生物医药可持续价值领航奖”等荣誉。","listedPrice":5.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华东医药,000963,华东医药股票,华东医药股票老虎,华东医药股票老虎国际,华东医药行情,华东医药股票行情,华东医药股价,华东医药股市,华东医药股票价格,华东医药股票交易,华东医药股票购买,华东医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}